Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q1

4886.TEDINET S100OVV1
Period2022-04-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥15.3bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥14.2bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥1.7bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥1.2bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.8bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.3bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.8bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥1.3bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥1.1bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥84.8bnat 2022-06-30Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥81.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥34.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥50.5bnat 2022-06-30Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥45.3bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥17.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥46.942022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.722021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥29m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥18m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥169m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥124m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥15m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥30m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥12m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30−¥2m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥12m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥12m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥160m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.4bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.4bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥103m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.8bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥12.8bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥12m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 325
ItemContextValueUnit
Current liabilitiesCurrentQuarterInstant17978000000JPY
Long term loans payablePrior1YearInstant12323000000JPY
Long term loans payableCurrentQuarterInstant10198000000JPY
Net defined benefit liabilityPrior1YearInstant5730000000JPY
Net defined benefit liabilityCurrentQuarterInstant5782000000JPY
Other nclPrior1YearInstant338000000JPY
Other nclCurrentQuarterInstant328000000JPY
Noncurrent liabilitiesPrior1YearInstant18393000000JPY
Noncurrent liabilitiesCurrentQuarterInstant16309000000JPY
LiabilitiesPrior1YearInstant34404000000JPY
LiabilitiesCurrentQuarterInstant34287000000JPY
Capital stockPrior1YearInstant1197000000JPY
Capital stockCurrentQuarterInstant1197000000JPY
Capital surplusPrior1YearInstant1867000000JPY
Capital surplusCurrentQuarterInstant1867000000JPY
Retained earningsPrior1YearInstant45833000000JPY
Retained earningsCurrentQuarterInstant46930000000JPY
Treasury stockPrior1YearInstant-3479000000JPY
Treasury stockCurrentQuarterInstant-3461000000JPY
Shareholders equityPrior1YearInstant45419000000JPY
Shareholders equityCurrentQuarterInstant46534000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant3231000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant3554000000JPY
Foreign currency translation adjustmentPrior1YearInstant164000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant303000000JPY
Remeasurements of defined benefit plansPrior1YearInstant77000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant84000000JPY
Valuation and translation adjustmentsPrior1YearInstant3473000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant3942000000JPY
Net assetsPrior1YearInstant48892000000JPY
Net assetsCurrentQuarterInstant50477000000JPY
Liabilities and net assetsPrior1YearInstant83297000000JPY
Liabilities and net assetsCurrentQuarterInstant84764000000JPY
Net salesPrior1YTDDuration14221000000JPY
Net salesCurrentYTDDuration15269000000JPY
Cost of salesPrior1YTDDuration7531000000JPY
Cost of salesCurrentYTDDuration8017000000JPY
Gross profitPrior1YTDDuration6690000000JPY
Gross profitCurrentYTDDuration7252000000JPY
Selling general and administrative expensesPrior1YTDDuration5501000000JPY
Selling general and administrative expensesCurrentYTDDuration5587000000JPY
Operating incomePrior1YTDDuration1188000000JPY
Operating incomeCurrentYTDDuration1664000000JPY
Interest income noiPrior1YTDDuration0JPY
Interest income noiCurrentYTDDuration0JPY
Dividends income noiPrior1YTDDuration130000000JPY
Dividends income noiCurrentYTDDuration177000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration64000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration39000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass